SCHEMBL5338230

SCHEMBL5338230

Brc1ccccc1OC1CCCCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 2/20 0.45
CARM1 Q86X55 2/20 0.43
PRMT1 Q99873 2/20 0.43
KMT2A Q03164 3/20 0.43
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MEN1 O00255 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HRH1 P35367 1/20 0.40
RAB9A P51151 1/20 0.39
PDE5A O76074 1/20 0.39
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
LNPEP Q9UIQ6 1/20 0.39
THRA P10827 1/20 0.38
THRB P10828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1926850 0.98 KMT2A (0.44) MCHR1CARM1PRMT1KMT2ALMNA
SCHEMBL16333708 0.94 HRH1 (0.41) MCHR1CARM1PRMT1KMT2ALMNA
SCHEMBL31652114 0.90 HRH1 (0.43) KMT2ALMNAHPGDHTTSMN1; SMN2
SCHEMBL2404772 0.90 HRH1 (0.43) KMT2ALMNAHPGDHTTSMN1; SMN2
SCHEMBL2242864 0.85 MCHR1 (0.51) MCHR1CARM1PRMT1HPGDHRH1
SCHEMBL5344402 0.83 MCHR1 (0.49) MCHR1CARM1PRMT1HRH1PDE5A
SCHEMBL14857935 0.82 HPGD (0.47) MCHR1CARM1PRMT1KMT2AHPGD
SCHEMBL31448509 0.82 MCHR1 (0.51) MCHR1CARM1PRMT1KMT2AHPGD
SCHEMBL14857739 0.82 MCHR1 (0.44) MCHR1CARM1PRMT1KMT2ALMNA
SCHEMBL14857951 0.82 MCHR1 (0.44) MCHR1CARM1PRMT1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3495359-A1 FLAP MODULATORS Janssen Pharmaceutica NV (BE) 2019-06-12 EP disclosed
EP-3070085-B1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-01-09 EP disclosed
CN-105669731-A Synthesis method of 4-(4-alkyl cyclohexyloxy)phenylboronic acid 沧州普瑞东方科技有限公司 2016-06-15 CN disclosed
WO-2014121055-A2 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-08-07 WO disclosed
US-7291619-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-11-06 US disclosed
EP-1368340-B1 PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS LILLY CO ELI (US) 2005-08-10 EP disclosed
US-20040092507-A1 Melanocortin receptor agonists ELI LILLY AND COMPANY 2004-05-13 US disclosed
EP-1368340-A1 PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2003-12-10 EP disclosed
WO-2002059108-A1 MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2002-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092507-A1 Melanocortin receptor agonists MC1R, MC4R, MC5R MCHR1 6/4885CARM1 4621/4885PRMT1 1436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.